Erik Rytter Ottosen
Leo Pharma
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Erik Rytter Ottosen.
Bioorganic & Medicinal Chemistry Letters | 1997
Charlotte Schou; Erik Rytter Ottosen; Hans Petersen; Fredrik Björkling; Scilla Latini; Pernille Vig Hjarnaa; Erik Bramm; Lise Binderup
4-Pyridyl cyanoguanidines with hydrophobic aromatic side chains showed potent antiproliferative activity in the human breast and lung cancer cell lines MCF-7, NYH and H460. In vivo, treatment with N-(6-chlorophenoxyhexyl)-N′-cyano-N″-4-pyridylguanidine (18, 20 mg/kg/day po.), gave a complete remission of tumours in a model of NYH inoculated nude mice.
Biochemical Pharmacology | 2000
Sara Ekelund; Gunnar Liminga; Fredrik Björkling; Erik Rytter Ottosen; Charlotte Schou; Lise Binderup; Rolf Larsson
CHS 828, a newly recognized pyridyl cyanoguanidine, has shown promising antitumor activity both in vitro and in vivo and is presently in early phase I clinical trial in collaboration with EORTC. In this study, the effects of CHS 828 and a series of analogues on extracellular acidification and cytotoxicity were compared with those of m-iodobenzylguanidine (MIBG) in human tumor cells. The extracellular acidification rate was measured using the Cytosensor microphysiometer, and determination of cytotoxicity and proliferation was [(14)C] performed by the fluorometric microculture cytotoxicity assay (FMCA) and measurement of [(14)C]thymidine and leucine uptake. CHS 828 significantly increased the acidification rate during the first 15-24 hr in a concentration-dependent manner. This effect was abolished by removal of glucose from the medium, substituted with 10 mM of pyruvate, indicating stimulated glycolysis as the source of the increased acidification rate. However, CHS 828 induced cytotoxicity at concentrations well below those that affected the rate of acidification; when a series of closely related pyridylguanidine analogues were tested and compared, no apparent relationship between cytotoxicity and acidification could be discerned. Furthermore, comparable increases in the acidification rate were evident in one subline with high-grade resistance to the cytotoxic actions of CHS 828. The results indicate that CHS 828 may share the inhibitory actions of MIBG on mitochondrial respiration with a subsequent increase in glycolysis and acidification rate. However, this mechanism of action appears neither necessary nor sufficient to fully explain the cytotoxic actions of CHS 828 in human tumor cells, actions which remain to be mechanistically clarified.
Journal of Medicinal Chemistry | 2003
Erik Rytter Ottosen; Morten Dahl Sørensen; Fredrik Björkling; Tine Skak-Nielsen; Marianne Scheel Fjording; Helle Aaes; Lise Binderup
Archive | 2010
Simon Feldbaek Nielsen; Daniel Rodriguez Greve; Carsten Ryttersgaard; Gunnar Grue-Sørensen; Erik Rytter Ottosen; Tina Dahlerup Poulsen; Søren Christian Schou; Anthony Murray
Archive | 1998
Charlotte Schou; Erik Rytter Ottosen
Archive | 2004
Erik Rytter Ottosen; Anne Marie Horneman; Xifu Liang; Soeren Christian Schou; Sophie Elisabeth Havez; Thomas Peter Sabroe
Archive | 2000
Erik Rytter Ottosen
Archive | 1998
Erik Rytter Ottosen; Schneur Rachlin
Archive | 2005
Erik Rytter Ottosen
Archive | 2017
Anthony Murray; Carsten Ryttersgaard; Daniel Rodriguez Greve; Erik Rytter Ottosen; Gunnar Grue-Sørensen; Simon Feldbaek Nielsen; Søren Christian Schou; Tina Dahlerup Poulsen